Your browser doesn't support javascript.
loading
Receptor binding and escape from Beta antibody responses drive Omicron-B.1.1.529 evolution
Wanwisa Dejnirattisai; Jiandong Huo; Daming Zhou; Jiri Zahradni_k; Piyada Supasa; Chang Liu; Helen M. E. Duyvesteyn; Helen Ginn; Alexander J. Mentzer; Aekkachai Tuekprakhon; Rungtiwa Nutalai; Beibei - Wang; Aiete Dijokaite; Suman Khan; Ori Avinoam; Mohammad Bahar; Donal Skelly; Sandra Adele; Sile Johnson; Ali Amini; Thomas Ritter; Chris Mason; Christina Dold; Danile Pan; Sara Assadi; Adam Bellass; Nikki Omo-Dare; David Koeckerling; Amy Flaxman; Daniel Jenkin; Parvinder K Aley; Merryn Voysey; Sue Ann Costa Clemens; Felipe Gomes Naveca; Valdinete Nascimento; Fernanda Nascimento; Cristiano Fernandes da Costa; Paola Cristina Resende; Alex Pauvolid-Correa; Marilda M. Siqueira; Vicky Baillie; Natali Serafin; Zanele Ditse; Kelly Da Silva; Shabir Madhi; Marta C Nunes; Tariq Malik; Peter JM Openshaw; J Kenneth Baillie; Malcolm G Semple; Alain R Townsend; Kuan-Ying A. Huang; Tiong Kit Tan; Miles W. Carroll; Paul Klenerman; Eleanor Barnes; Susanna J. Dunachie; Bede Constantinides; Hermione Webster; Derrick Crook; Andrew J. Pollard; Teresa Lambe; - OPTIC Consortium; - ISARIC4C; Neil G. Paterson; Mark A. Williams; David R. Hall; Elizabeth E Fry; Juthathip Mongkolsapaya; Jingshan Ren; Gideon Schreiber; David I. Stuart; Gavin R. Screaton.
Affiliation
  • Wanwisa Dejnirattisai; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7BN, UK
  • Jiandong Huo; Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK
  • Daming Zhou; Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Headington, Oxford, UK.
  • Jiri Zahradni_k; Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel
  • Piyada Supasa; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7BN, UK
  • Chang Liu; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7BN, UK
  • Helen M. E. Duyvesteyn; Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Headington, Oxford, UK.
  • Helen Ginn; Diamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot, UK.
  • Alexander J. Mentzer; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7BN, UK
  • Aekkachai Tuekprakhon; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7BN, UK
  • Rungtiwa Nutalai; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7BN, UK
  • Beibei - Wang; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7BN, UK
  • Aiete Dijokaite; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7BN, UK
  • Suman Khan; Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel
  • Ori Avinoam; Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel
  • Mohammad Bahar; Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK
  • Donal Skelly; Peter Medawar Building for Pathogen Research,Nuffield Deptment of Medicine, University of Oxford, UK
  • Sandra Adele; Peter Medawar Building for Pathogen Research, Oxford, UK
  • Sile Johnson; Peter Medawar Building for Pathogen Research
  • Ali Amini; Oxford University Hospitals NHS Foundation Trust, Oxford, UK
  • Thomas Ritter; Oxford University Hospitals NHS Foundation Trust
  • Chris Mason; Oxford University Hospitals NHS Foundation Trust
  • Christina Dold; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, OX3 7LE, UK.
  • Danile Pan; Department of Infectious Diseases and HIV Medicine, University Hospitals of Leicester NHS Trust
  • Sara Assadi; Department of Infectious Diseases and HIV Medicine, University Hospitals of Leicester NHS Trust
  • Adam Bellass; Department of Infectious Diseases and HIV Medicine, University Hospitals of Leicester NHS Trust
  • Nikki Omo-Dare; Department of Infectious Diseases and HIV Medicine, University Hospitals of Leicester NHS Trust
  • David Koeckerling; Medical Sciences Division, University of Oxford
  • Amy Flaxman; Jenner Institute, Nuffield Department of Medicine, University of Oxford, UK
  • Daniel Jenkin; Jenner Institute, Nuffield Department of Medicine, University of Oxford, UK
  • Parvinder K Aley; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, OX3 7LE, UK.
  • Merryn Voysey; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, OX3 7LE
  • Sue Ann Costa Clemens; Institute of Global Health, University of Siena, Siena, Brazil; Department of Paediatrics, University of Oxford, Oxford, UK.
  • Felipe Gomes Naveca; Laborato rio de Ecologia de Doencas Transmissveis na Amazonia, Instituto Leonidas e Maria Deane, FIOCRUZ, Manaus, Amazonas, Brazil
  • Valdinete Nascimento; Laborato rio de Ecologia de Doencas Transmissveis na Amazonia, Instituto Leonidas e Maria Deane, FIOCRUZ, Manaus, Amazonas, Brazil
  • Fernanda Nascimento; Laboratorio de Ecologia de Doencas Transmissiveis na Amazonia, Instituto Leonidas e Maria Deane, FIOCRUZ, Manaus, Amazonas, Brazil
  • Cristiano Fernandes da Costa; Fundacao de Vigilancia em Saude do Amazonas, Manaus, Amazonas, Brazil
  • Paola Cristina Resende; Laboratory of Respiratory Viruses and Measles, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Brazil
  • Alex Pauvolid-Correa; Laboratory of Respiratory Viruses and Measles, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Brazil
  • Marilda M. Siqueira; Laboratory of Respiratory Viruses and Measles, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Brazil
  • Vicky Baillie; South African MRC, Vaccines and Infectious Diseases Analytics Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, J
  • Natali Serafin; South African MRC, Vaccines and Infectious Diseases Analytics Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, J
  • Zanele Ditse; South African MRC, Vaccines and Infectious Diseases Analytics Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, J
  • Kelly Da Silva; South African MRC, Vaccines and Infectious Diseases Analytics Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, J
  • Shabir Madhi; South African MRC, Vaccines and Infectious Diseases Analytics Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, J
  • Marta C Nunes; South African MRC, Vaccines and Infectious Diseases Analytics Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, J
  • Tariq Malik; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK
  • Peter JM Openshaw; National Heart & Lung Institute, Imperial College London
  • J Kenneth Baillie; Genetics and Genomics, Roslin Institute, University of Edinburgh, Edinburgh, UK
  • Malcolm G Semple; NIHR Health Protection Research Unit, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool,
  • Alain R Townsend; MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DS, UK
  • Kuan-Ying A. Huang; Research Center for Emerging Viral Infections, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
  • Tiong Kit Tan; MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DS, UK
  • Miles W. Carroll; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7BN, UK
  • Paul Klenerman; Peter Medawar Building for Pathogen Research,Nuffield Deptment of Medicine, University of Oxford, UK
  • Eleanor Barnes; Peter Medawar Building for Pathogen Research, Nuffield Deptment of Medicine, University of Oxford, UK
  • Susanna J. Dunachie; Peter Medawar Building for Pathogen Research,Nuffield Deptment of Medicine, University of Oxford, UK
  • Bede Constantinides; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Hermione Webster; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Derrick Crook; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Andrew J. Pollard; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, OX3 7LE, UK.
  • Teresa Lambe; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, OX3 7LE, UK.
  • - OPTIC Consortium; -
  • - ISARIC4C; -
  • Neil G. Paterson; Diamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot, UK.
  • Mark A. Williams; Diamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot, UK.
  • David R. Hall; Diamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot, UK.
  • Elizabeth E Fry; Division of Structural Biology, Nuffield Department of Medicine,
  • Juthathip Mongkolsapaya; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7BN, UK
  • Jingshan Ren; Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Headington, Oxford, UK.
  • Gideon Schreiber; Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel
  • David I. Stuart; Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Headington, Oxford, UK.
  • Gavin R. Screaton; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7BN, UK
Preprint in En | PREPRINT-BIORXIV | ID: ppbiorxiv-471045
ABSTRACT
On the 24th November 2021 the sequence of a new SARS CoV-2 viral isolate spreading rapidly in Southern Africa was announced, containing far more mutations in Spike (S) than previously reported variants. Neutralization titres of Omicron by sera from vaccinees and convalescent subjects infected with early pandemic as well as Alpha, Beta, Gamma, Delta are substantially reduced or fail to neutralize. Titres against Omicron are boosted by third vaccine doses and are high in cases both vaccinated and infected by Delta. Mutations in Omicron knock out or substantially reduce neutralization by most of a large panel of potent monoclonal antibodies and antibodies under commercial development. Omicron S has structural changes from earlier viruses, combining mutations conferring tight binding to ACE2 to unleash evolution driven by immune escape, leading to a large number of mutations in the ACE2 binding site which rebalance receptor affinity to that of early pandemic viruses.
License
cc_by
Fulltext
Add to My VHL
Print
XML
Search on Google
Full text: 1 Collection: 09-preprints Database: PREPRINT-BIORXIV Language: En Year: 2021 Document type: Preprint
Fulltext
Add to My VHL
Print
XML
Search on Google
Full text: 1 Collection: 09-preprints Database: PREPRINT-BIORXIV Language: En Year: 2021 Document type: Preprint